{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:18:21Z","timestamp":1765887501995,"version":"3.44.0"},"reference-count":38,"publisher":"BMJ","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Qual Saf"],"accepted":{"date-parts":[[2013,4,3]]},"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The official prescribing information document distributed with a prescription drug is a key source of safety information, but it may include excessive or insufficient details.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare prescribing information approved by the US Food and Drug Administration with the UK, Canada and Australia to identify content differences in safety warnings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>For 20 top-selling prescription drugs, we used an automated natural language processing tool to calculate the number and severity of reported adverse drug reactions (ADRs). We fit hierarchical Poisson models and included fixed effects for other prescribing information characteristics. Separately, we analysed the appearance and content of \u2018black box\u2019 warnings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There was substantial variation in safety content of approved prescribing information. Canada had the highest median ADRs per drug (138 (IQR 86\u2013234)) and the UK had the lowest (84 (IQR 51\u2013111)). The number of ADRs reported was on average 50% higher in Canada compared with the USA (ratio of ADRs\/document: 1.5, 95% CI 1.4 to 1.6, p&lt;0.001). By contrast, there were on average 15% fewer ADRs listed in the UK compared with the USA (ratio of ADRs\/document 0.85 (95% CI 0.78 to 0.93, p&lt;0.001), and 21% fewer ADRs listed in Australia compared with the USS (ratio of ADRs\/document 0.79, 95% CI 0.74 to 0.85, p&lt;0.001). There were no variations in ADR severity. The presence and qualitative content of boxed warnings also showed substantial diversity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>International variations exist in the presentation of safety data in drug prescribing information, which may have important implications for patient safety. Better international coordination is necessary to enhance use of this information for patient decision-making.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjqs-2012-001704","type":"journal-article","created":{"date-parts":[[2013,4,25]],"date-time":"2013-04-25T22:47:04Z","timestamp":1366930024000},"page":"727-734","source":"Crossref","is-referenced-by-count":28,"title":["Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs"],"prefix":"10.1136","volume":"22","author":[{"given":"Aaron S","family":"Kesselheim","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica M","family":"Franklin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Avorn","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon D","family":"Duke","sequence":"additional","affiliation":[{"name":"Regenstrief Institute and Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,4,25]]},"reference":[{"key":"2025090412385793000_22.9.727.1","unstructured":"Department of Health and Human Services. Requirements on content and format of labeling for human prescription drug and biological products . 21 C.F.R. 201.56. Silver Spring, MD: US Food and Drug Administration, 2011."},{"key":"2025090412385793000_22.9.727.2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070130"},{"key":"2025090412385793000_22.9.727.3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.61.1.11"},{"key":"2025090412385793000_22.9.727.4","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.167"},{"key":"2025090412385793000_22.9.727.5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.10.1076"},{"issue":"Suppl 1","key":"2025090412385793000_22.9.727.6","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1136\/qhc.0100009","article-title":"Understanding risk and lessons for clinical risk communication about treatment preferences","volume":"10","author":"Edwards","year":"2001","journal-title":"Qual Health Care"},{"key":"2025090412385793000_22.9.727.7","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/ajhp\/60.10.1012","article-title":"Pharmacist involvement in a multidisciplinary inpatient medication education program","volume":"60","author":"Calabrese","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"2025090412385793000_22.9.727.8","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.6.747"},{"key":"2025090412385793000_22.9.727.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068119"},{"key":"2025090412385793000_22.9.727.10","first-page":"847","article-title":"Adequate drug warnings in the face of uncertain causality: the learned intermediary doctrine and the need for clarity","volume":"107","author":"Imbroscio","year":"2005","journal-title":"West Virginia Law Rev"},{"key":"2025090412385793000_22.9.727.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0907708"},{"key":"2025090412385793000_22.9.727.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.01.007"},{"key":"2025090412385793000_22.9.727.13","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2105\/AJPH.77.12.1518","article-title":"Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene","volume":"77","author":"Soumerai","year":"1987","journal-title":"Am J Public Health"},{"key":"2025090412385793000_22.9.727.14","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.182"},{"key":"2025090412385793000_22.9.727.15","unstructured":"Avorn J . Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Alfred A Knopf, 2004."},{"key":"2025090412385793000_22.9.727.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1208781"},{"key":"2025090412385793000_22.9.727.17","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.3.491"},{"key":"2025090412385793000_22.9.727.18","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3351"},{"key":"2025090412385793000_22.9.727.19","unstructured":"DailyMed: about DailyMed. http:\/\/dailymed.nlm.nih.gov\/dailymed\/about.cfm (accessed 16 Apr 2013)."},{"key":"2025090412385793000_22.9.727.20","unstructured":"Government of Canada HC. Drug Product Database Online Query. http:\/\/webprod5.hc-sc.gc.ca\/dpd-bdpp (accessed 17 Apr 2013)."},{"key":"2025090412385793000_22.9.727.21","unstructured":"What's new\u2014Electronic Medicines Compendium (eMC). http:\/\/www.medicines.org.uk\/emc\/ (accessed 16 Apr 2013)."},{"key":"2025090412385793000_22.9.727.22","unstructured":"Australian Government Department of Health and Ageing. Information about prescription medicines in Australia. https:\/\/www.ebs.tga.gov.au (accessed 17 Apr 2013)."},{"key":"2025090412385793000_22.9.727.23","unstructured":"Bartholomew M . Top 200 prescription drugs of 2009. http:\/\/www.pharmacytimes.com\/publications\/issue\/2010\/May2010\/RxFocusTopDrugs-0510 (accessed 16 Apr 2013)."},{"key":"2025090412385793000_22.9.727.24","unstructured":"Center for Drug Evaluation and Research. Drugs@FDA data files. http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ucm079750.htm (accessed 16 Apr 2013)."},{"key":"2025090412385793000_22.9.727.25","first-page":"177","article-title":"ADESSA: a real-time decision support service for delivery of semantically coded adverse drug event data","volume":"2010","author":"Duke","year":"2010","journal-title":"AMIA Annu Symp Proc"},{"key":"2025090412385793000_22.9.727.26","unstructured":"First DataBank . FDB MedKnowledge. http:\/\/www.fdbhealth.com\/fdb-medknowledge-clinical-modules\/ (accessed 16 Apr 2013)."},{"key":"2025090412385793000_22.9.727.27","unstructured":"R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011."},{"key":"2025090412385793000_22.9.727.28","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2007.06141"},{"key":"2025090412385793000_22.9.727.29","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.593523"},{"key":"2025090412385793000_22.9.727.30","unstructured":"HealthCanada. Transparency\u2014release of product monographs directly to requesters. 29 May 2006. http:\/\/www.hc-sc.gc.ca\/dhp-mps\/alt_formats\/hpfb-dgpsa\/pdf\/prodpharma\/pm_notice_mp_avis_trans-eng.pdf (accessed 16 Apr 2013)."},{"key":"2025090412385793000_22.9.727.31","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1825"},{"key":"2025090412385793000_22.9.727.32","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2006.087262"},{"key":"2025090412385793000_22.9.727.33","unstructured":"Berenson A . For Merck, the Vioxx paper trail won't go away. NY Times 21 August 2005; A1."},{"key":"2025090412385793000_22.9.727.34","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.340"},{"key":"2025090412385793000_22.9.727.35","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.3.338"},{"key":"2025090412385793000_22.9.727.36","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.28.3.724"},{"key":"2025090412385793000_22.9.727.37","first-page":"199","article-title":"ICH Harmonised Tripartite Guideline: guideline for good clinical practice","volume":"47","author":"International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use","year":"2001","journal-title":"J Postgrad Med"},{"key":"2025090412385793000_22.9.727.38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020042"}],"container-title":["BMJ Quality &amp; Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjqs-2012-001704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T19:39:06Z","timestamp":1757014746000},"score":1,"resource":{"primary":{"URL":"https:\/\/qualitysafety.bmj.com\/lookup\/doi\/10.1136\/bmjqs-2012-001704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,25]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,8,13]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1136\/bmjqs-2012-001704"],"URL":"https:\/\/doi.org\/10.1136\/bmjqs-2012-001704","relation":{},"ISSN":["2044-5415","2044-5423"],"issn-type":[{"type":"print","value":"2044-5415"},{"type":"electronic","value":"2044-5423"}],"subject":[],"published":{"date-parts":[[2013,4,25]]}}}